302
Participants
Start Date
November 18, 2021
Primary Completion Date
February 5, 2027
Study Completion Date
February 5, 2027
MenABCWY vaccine
Two doses of the MenABCWY vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, on a 0-, 24-month schedule in the ABCWY-24 Group, and a 0-, 48-month schedule in the ABCWY-48 Group.
Placebo
Single dose of Placebo (saline solution in pre-filled syringe), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1441 in the ABCWY-24 Group, and at Day 721 in the ABCWY-48 Group.
GSK Investigational Site, Endwell
GSK Investigational Site, Binghamton
GSK Investigational Site, Leipzig
GSK Investigational Site, Washington D.C.
GSK Investigational Site, Charlotte
GSK Investigational Site, Charleston
GSK Investigational Site, Macon
GSK Investigational Site, Miami
GSK Investigational Site, Miami
GSK Investigational Site, Birmingham
GSK Investigational Site, Kingsport
GSK Investigational Site, Nicholasville
GSK Investigational Site, Bramsche
GSK Investigational Site, Missoula
GSK Investigational Site, Omaha
GSK Investigational Site, Mannheim
GSK Investigational Site, Lincoln
GSK Investigational Site, Grand Island
GSK Investigational Site, Haughton
GSK Investigational Site, Austin
GSK Investigational Site, Herxheim
GSK Investigational Site, Schweigen-Rechtenbach
GSK Investigational Site, Missoula
GSK Investigational Site, Schönau am Königssee
GSK Investigational Site, Layton
GSK Investigational Site, Valparaiso
GSK Investigational Site, Tucson
GSK Investigational Site, Ventura
GSK Investigational Site, Gresham
GSK Investigational Site, Galveston
Lead Sponsor
GlaxoSmithKline
INDUSTRY